Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Single Blood Test Could Screen for Several Cancers

By LabMedica International staff writers
Posted on 17 Nov 2014
A laboratory test that can screen for multiple cancer types from a single blood sample could be developed after hundreds of compounds have been identified in the blood of cancer patients.

All cancers produce compounds that end up in the bloodstream, so it is feasible that such blood markers could form the basis of a general screening test for many different forms of cancer.

Scientist led by those at the University of Warwick Medical School (Coventry, UK) conducted a systematic mapping review to establish what biomarkers exist that could be used to develop a general cancer screening assay from blood sampling and what is their state of development. More...
Electronic searches of several relevant databases were conducted in May 2014. Altogether, they reviewed 19,000 scientific papers and identified more than 800 markers in the blood of cancer patients.

In the UK, survival rates for cancer are lower than in some other western countries, part of which may be related to late diagnosis. Developing more ways to spot cancers earlier, including studies into new screening technologies such as this, could help give more options for curative treatment, and save more lives in the future. In the UK, cancer is most often detected after patients present symptoms to their doctor, with a small proportion being detected through any of the three national screening programs for breast, bowel, and cervical cancer. This study could open the way for less invasive, new screening tests that could detect more cancers, possibly including some rare types, at an early stage when they are more likely to be treatable.

One of the studies reviewed examined plasma and bile from 77 patients with pancreatic ductal adenocarcinoma (PDAC), 67 with chronic pancreatitis and 71 healthy controls, and compared their levels of expression of 10 candidate micro ribonucleic acid (miRNAs) Their analysis showed increased expression of miRNA-10b, -155, and -106b in plasma and appears to be highly accurate in diagnosing PDAC.

Ian Cree, MD, PhD, a professor of Pathology and senior author of the study, said, “This is a new approach to early detection and the first time such a systematic review has been done. A single blood-based screening test would be a game changer for early detection of cancer which could help make it a curable disease for many more patients. We believe that we've identified all the relevant biomarkers; the next step is working out which ones work the best for spotting cancers.” The study was presented at the NCRI Cancer Conference, held November 2–5, 2014, in Liverpool (UK).

Related Links:

University of Warwick Medical School 



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
Collection and Transport System
PurSafe Plus®
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.